Implandata Announces Closing of €3M Series B-Round, Establishment of Fully Owned USA Subsidiary and Progress in Clinical Program

27.10.2014

Hannover, Germany, October 27, 2014 / B3C newswire / – Implandata Ophthalmic Products GmbH (Implandata) an ophthalmic surgical product and e-Health start-up company announces the closing of a €3M Series B-Round. Born2Grow Venture Partners, a private fund based in Heilbronn/Germany joins in as new investor. Previous investors Peppermint Charité Beteiligungsfonds/Berlin, Hannover Beteiligungsfonds/Hannover, High-Tech Gründerfonds/Bonn, KfW/Bonn and a group of Business Angels complete the Series B funding round.

Weblink

 

Kategorie: Pressemitteilungen